Emerging proteomics biomarkers and prostate cancer burden in Africa

Various biomarkers have emerged via high throughput omics-based approaches for use in diagnosis, treatment, and monitoring of prostate cancer. Many of these have yet to be demonstrated as having value in routine clinical practice. Moreover, there is a dearth of information on validation of these eme...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2017-06, Vol.8 (23), p.37991-38007
Main Authors: Adeola, Henry A, Blackburn, Jonathan M, Rebbeck, Timothy R, Zerbini, Luiz F
Format: Article
Language:English
Subjects:
Africa
Biomarkers - metabolism
Humans
Male
Mass Spectrometry - methods
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - genetics
Proteomics - methods
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Various biomarkers have emerged via high throughput omics-based approaches for use in diagnosis, treatment, and monitoring of prostate cancer. Many of these have yet to be demonstrated as having value in routine clinical practice. Moreover, there is a dearth of information on validation of these emerging prostate biomarkers within African cohorts, despite the huge burden and aggressiveness of prostate cancer in men of African descent. This review focusses of the global landmark achievements in prostate cancer proteomics biomarker discovery and the potential for clinical implementation of these biomarkers in Africa. Biomarker validation processes at the preclinical, translational and clinical research level are discussed here, as are the challenges and prospects for the evaluation and use of novel proteomic prostate cancer biomarkers.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.16568